Tuesday , April 24 2018
Home / Multiple Sclerosis

Multiple Sclerosis

Prime Therapeutics Finds Poor Adherence to High-Cost Multiple Sclerosis Therapy

PAUL, Minn., April 23, 2018 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime), using real-world integrated medical and pharmacy data, show members with multiple sclerosis (MS) had 8.3 times higher annual total health care expense than members without MS. More than 80 percent of the …

Read More »

Ocrevus Significantly Reduces Disease Activity and Disability Progression in Relapsing Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple …

Read More »

FDA Grants Breakthrough Therapy Designation to Novartis’ Fingolimod for Pediatric Multiple Sclerosis

EAST HANOVER, N.J., Dec. 18, 2017 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS). Fingolimod, also known as Gilenya® in …

Read More »

Biogen and Alkermes Partner to Develop and Commercialize Multiple Sclerosis Drug ALKS 8700

CAMBRIDGE, Mass. & DUBLIN–(BUSINESS WIRE)–Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS). “This …

Read More »

Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate

Paris, France and South San Francisco, Calif – November 9, 2017 – Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) …

Read More »

Studies Find Approximately Half of Patients Do Not Always Engage with Healthcare Professionals During Multiple Sclerosis Relapse

STAINES-UPON-THAMES, United Kingdom, Oct. 27, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced results from two company-sponsored surveys – the Multiple Sclerosis in America 2017 Survey (Poster P805) and a national patient survey conducted by Harris Poll (Poster P1267) – that suggest patient-reported …

Read More »

Data Suggests Slowing of Cortical Gray Matter Atrophy with Aubagio Delays Conversion to Clinically Definitive Multiple Sclerosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new investigational data that suggest slowing of cortical gray matter volume loss (atrophy) with Aubagio® (teriflunomide) is associated with delayed conversion to clinically definite multiple sclerosis (CDMS). The data, from the Phase III TOPIC study in patients with …

Read More »

Abzena and UGA Biopharma Team Up to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

CAMBRIDGE, England & HENNIGSDORF, Germany–(BUSINESS WIRE)–Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line …

Read More »

FDA Approves Mylan’s Generic Version of Teva’s Multiple Sclerosis Drug Copaxone

HERTFORDSHIRE, England, and PITTSBURGH, Oct. 3, 2017 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection, an AP-rated, substitutable generic version of Teva’s Copaxone® 40 …

Read More »

Unique Gene Therapy Prevents, Reverses Multiple Sclerosis in Animal Model

Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found. By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. …

Read More »